Prosecution Insights
Last updated: November 12, 2026
Application No. 18/578,875

SMALL MOLECULES INHIBITORS OF CYCLIC GMP-AMP SYNTHASE (cGAS)

Final Rejection §102§103
Filed
Jan 12, 2024
Priority
Jul 13, 2021 — provisional 63/203,219 +2 more
Examiner
KIM, SEONG JONG
Art Unit
1621
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Shangpharma Innovation Inc.
OA Round
2 (Final)
20%
Grant Probability
At Risk
3-4
OA Rounds
20%
With Interview

Examiner Intelligence

Grants only 20% of cases
20%
Career Allowance Rate
1 granted / 5 resolved
-40.0% vs TC avg
Minimal +0% lift
Without
With
+0.0%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
59 currently pending
Career history
59
Total Applications
across all art units

Office Action

§102 §103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION This action is FINAL. Claim Status Claims 1-42 are pending. Claims 25, 31-34, and 36-42 are examined herein. Claims 1-24, 26-30, and 35 are withdrawn (see restriction/election in the previous office action). Priority This application is filed 1/12/2024 and claims the benefit of domestic priority as below: PNG media_image1.png 58 512 media_image1.png Greyscale Information Disclosure Statements One IDS(s) received on 4/2/2026 has been considered unless marked with a strikethrough. No new IDS(s) have been provided since the last office action. Response to Arguments Applicant's arguments/amendments filed on 08/05/2026, and in the amendments, claims 1, 3-13, 16-17, 19, 21, 23, 25, 28-38, 40 and 41 are currently amended, and claim 42 is newly added. No new matter has been added to the application. With respect to the objection of claims, the amendments and arguments have been fully considered and are persuasive. Therefore, the objection of claims has been withdrawn. With respect to the rejection of claims 25, and 39 under 35 U.S.C. 102, the arguments/ amendments have been fully considered and are persuasive. Therefore, the rejection of the claims 25, and 39 under 35 U.S.C. 102 has been withdrawn. With respect to the rejection of claim 40 under 35 U.S.C. 102, Applicant has amended the claim 40 to remove Compound 41 as an alternative species of the previous action. Accordingly, the previous rejection of the claim 40 under 35 U.S.C. 102 has been withdrawn. The Examiner conducted an additional prior art search directed to the other alternative species encompassed by amended claim 40. Accordingly, a new ground of rejection under 35 USC 102 is set forth below with respect to claim 40 based on the additional search. New Ground of Rejections Claim Interpretation Claims are interpreted in accordance with the broadest reasonable interpretation (BRI) standard consistent with the specification (See MPEP 2111). The product claims are interpreted to cover the compound per se. Any statement of use does not distinguish the claimed product from an otherwise identical prior art product. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 40 is rejected under 35 U.S.C. 102(a)(1) as being anticipated by commercial chemical databases (e.g., Chemical Abstracts Service RN: 1340967-08-9, REGISTRY Database, STN International, CAS, Columbus, Ohio, USA, entered STN database on 11/04/2011). With respect to claim 40, the claim recites the compound 2 in the table. The commercial chemical databases (e.g., Chemical Abstracts Service) disclose the compound 2. PNG media_image2.png 250 552 media_image2.png Greyscale PNG media_image3.png 440 726 media_image3.png Greyscale Compound 2 in claim 40 RN: 1340967-08-9 As the claim interpretation, the product claims are interpreted to cover the compound per se. Moreover, although the prior art reference does not explicitly disclose the functional property for the instant application, the prior art compound is structurally identical to the claimed compound. A prior art compound that is structurally identical to the claimed compound is presumed to possess the same inherent properties as the claimed compound. The discovery of a previously unrecognized property of a prior art compound does not render the old compound patentable. (See MPEP 2112) Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 42 is/are rejected under 35 U.S.C. 103 as being unpatentable over the calculated physicochemical properties of commercial chemical databases (e.g., Chemical Abstracts Service RN: 1340967-08-9, REGISTRY Database, STN International, CAS, Columbus, Ohio, USA, entered STN database on 11/04/2011) in view of Lowery et al. (WO 2020/142729 A1, pub'd 07/09/2020). With respect to claim 42, the claim recites that a pharmaceutical composition comprising a compound or pharmaceutically acceptable salt thereof according to claim 40 and a pharmaceutically acceptable carrier. The commercial chemical databases (e.g., Chemical Abstracts Service) disclose a compound (i.e., RN: 1340967-08-9) falling within the scope of claim 40, as discussed above. The calculated physicochemical properties of the compound include LogP = 1.058 at 25oC, Log D = 1.058 at pH 7.4 25oC, pKa = 16.172±0.30 in acidic and 2.000±0.40 in base at 25oC, and predicted aqueous solubility = 0.0032 mol/L (i.e., 3.2 mM) in unbuffered water at pH 7.041. The predicted aqueous solubility and relatively low LogP and LogD values indicate that the compound has measurable aqueous solubility and relatively low lipophilicity. These properties suggest that conventional pharmaceutical carriers could be considered for preparing a pharmaceutical composition comprising the compound, without necessarily requiring specialized solubility agents. However, the calculated physicochemical properties of the compound fail to teach a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier. Lowery teaches pharmaceutical compositions comprising cGAS inhibitors and pharmaceutically acceptable carriers, solvents, adjuvants or diluents (paragraph [0050]-[0053]). Lowery further teaches methods for preparing pharmaceutical formulations, including tablets, capsules, and aqueous suspensions using suitable pharmaceutically acceptable excipients as conventional formulation approaches (paragraph [0054]-[0059]). It would have been obvious to a PHOSITA at the time of the invention to formulate the compound with a conventional pharmaceutically acceptable carrier, as taught by Lowery, for the purpose of preparing a pharmaceutical composition using known formulation techniques. A PHOSITA would have been motivated to formulate the compound with a conventional pharmaceutically acceptable carrier in view of its calculated physicochemical properties, including its predicted aqueous solubility of 3.2 mM and relatively low LogP and LogD values, which suggest that the compound would be amenable to conventional pharmaceutical formulation techniques. Lowery teaches that pharmaceutical compositions can be prepared using conventional pharmaceutically acceptable carriers and excipients. (paragraph [0050]-[0059]). A PHOSITA would have had a reasonable expectation of successfully preparing a pharmaceutical composition comprising the compound and a conventional pharmaceutically acceptable carrier using known formulation techniques, because the calculated physicochemical properties of the compound suggest that conventional carriers could be used without necessarily requiring specialized solubilizing agents. Accordingly, the combination of the compound with a conventional pharmaceutically acceptable carrier would have been expected to yield a pharmaceutical composition using known formulation method. See MPEP 2143(I)(A). Conclusion Claim 40, and 42 are rejected. Claims 25, 31-34, 36-39, and 41 are allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SEONG JONG KIM whose telephone number is (571)272-6918. The examiner can normally be reached 7:00am-3:30pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Clinton A. Brooks can be reached at 571-270-7682. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SEONG JONG KIM/ Examiner, Art Unit 1621 /CLINTON A BROOKS/ Supervisory Patent Examiner, Art Unit 1621
Read full office action

Prosecution Timeline

Jan 12, 2024
Application Filed
May 05, 2026
Non-Final Rejection mailed — §102, §103
Aug 05, 2026
Response Filed
Oct 23, 2026
Final Rejection mailed — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12735447
PROCESS FOR PREPARING B-[(7alpha,17beta)-17-HYDROXY-7-[9-[(4,4,5,5,5-PENTAFLUOROPENTYL)SULFINYL]NONYL]ESTRA-1,3,5(10)-TRIEN-3-YL]-BORONIC ACID AND PROCESS INTERMEDIATES
2y 5m to grant Granted Sep 15, 2026
Study what changed to get past this examiner. Based on 1 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
20%
Grant Probability
20%
With Interview (+0.0%)
Moderate
PTA Risk
Based on 5 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month